228 related articles for article (PubMed ID: 8855792)
1. Immunocytochemical detection of p53 in human thyroid carcinomas is associated with mutation and immortalization of cell lines.
Jossart GH; Epstein HD; Shaver JK; Weier HU; Greulich KM; Tezelman S; Grossman RF; Siperstein AE; Duh QY; Clark OH
J Clin Endocrinol Metab; 1996 Oct; 81(10):3498-504. PubMed ID: 8855792
[TBL] [Abstract][Full Text] [Related]
2. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas.
Fagin JA; Matsuo K; Karmakar A; Chen DL; Tang SH; Koeffler HP
J Clin Invest; 1993 Jan; 91(1):179-84. PubMed ID: 8423216
[TBL] [Abstract][Full Text] [Related]
3. p53 mutations in all stages of thyroid carcinomas.
Zou M; Shi Y; Farid NR
J Clin Endocrinol Metab; 1993 Oct; 77(4):1054-8. PubMed ID: 8408453
[TBL] [Abstract][Full Text] [Related]
4. Mutation of the p53 gene in a differentiated human thyroid carcinoma cell line, but not in primary thyroid tumours.
Wright PA; Lemoine NR; Goretzki PE; Wyllie FS; Bond J; Hughes C; Röher HD; Williams ED; Wynford-Thomas D
Oncogene; 1991 Sep; 6(9):1693-7. PubMed ID: 1923534
[TBL] [Abstract][Full Text] [Related]
5. Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas.
Elisei R; Shiohara M; Koeffler HP; Fagin JA
Cancer; 1998 Nov; 83(10):2185-93. PubMed ID: 9827724
[TBL] [Abstract][Full Text] [Related]
6. Bax expression in benign and malignant thyroid tumours: dysregulation of wild-type P53 is associated with a high Bax and P21 expression in thyroid carcinoma.
Hermann S; Sturm I; Mrozek A; Klosterhalfen B; Hauptmann S; Dörken B; Daniel PT
Int J Cancer; 2001 Jun; 92(6):805-11. PubMed ID: 11351299
[TBL] [Abstract][Full Text] [Related]
7. Contribution of p53 gene alterations to development of metastatic forms of follicular thyroid carcinoma.
Sápi Z; Lukács G; Sztán M; Papp J; Oláh E
Diagn Mol Pathol; 1995 Dec; 4(4):256-60. PubMed ID: 8634781
[TBL] [Abstract][Full Text] [Related]
8. FHIT and TSG101 in thyroid tumours: aberrant transcripts reflect rare abnormal RNA processing events of uncertain pathogenetic or clinical significance.
McIver B; Grebe SK; Wang L; Hay ID; Yokomizo A; Liu W; Goellner JR; Grant CS; Smith DI; Eberhardt NL
Clin Endocrinol (Oxf); 2000 Jun; 52(6):749-57. PubMed ID: 10848880
[TBL] [Abstract][Full Text] [Related]
9. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
[TBL] [Abstract][Full Text] [Related]
10. Genetic mutations in thyroid carcinoma.
Taccaliti A; Boscaro M
Minerva Endocrinol; 2009 Mar; 34(1):11-28. PubMed ID: 19209125
[TBL] [Abstract][Full Text] [Related]
11. Alterations of p53 and expression of WAF1/p21 in human thyroid tumors.
Zedenius J; Larsson C; Wallin G; Bäckdahl M; Aspenblad U; Höög A; Børresen AL; Auer G
Thyroid; 1996 Feb; 6(1):1-9. PubMed ID: 8777377
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of mutations of ras and p53 in benign and malignant thyroid tumors from children exposed to radiation after the Chernobyl nuclear accident.
Nikiforov YE; Nikiforova MN; Gnepp DR; Fagin JA
Oncogene; 1996 Aug; 13(4):687-93. PubMed ID: 8761289
[TBL] [Abstract][Full Text] [Related]
13. The natural protein kinase C alpha mutant is present in human thyroid neoplasms.
Prévostel C; Alvaro V; de Boisvilliers F; Martin A; Jaffiol C; Joubert D
Oncogene; 1995 Aug; 11(4):669-74. PubMed ID: 7651730
[TBL] [Abstract][Full Text] [Related]
14. Mutations of the p53 gene in human functional adrenal neoplasms.
Lin SR; Lee YJ; Tsai JH
J Clin Endocrinol Metab; 1994 Feb; 78(2):483-91. PubMed ID: 8106638
[TBL] [Abstract][Full Text] [Related]
15. Lack of p16/CDKN2 alterations in thyroid carcinomas.
Yane K; Konishi N; Kitahori Y; Naito H; Okaichi K; Ohnishi T; Miyahara H; Matsunaga T; Hiasa Y
Cancer Lett; 1996 Mar; 101(1):85-92. PubMed ID: 8625287
[TBL] [Abstract][Full Text] [Related]
16. Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland.
Ito T; Seyama T; Mizuno T; Tsuyama N; Hayashi T; Hayashi Y; Dohi K; Nakamura N; Akiyama M
Cancer Res; 1992 Mar; 52(5):1369-71. PubMed ID: 1737400
[TBL] [Abstract][Full Text] [Related]
17. Is atypical follicular adenoma of the thyroid a preinvasive malignancy?
Tzen CY; Huang YW; Fu YS
Hum Pathol; 2003 Jul; 34(7):666-9. PubMed ID: 12874762
[TBL] [Abstract][Full Text] [Related]
18. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.
Xu X; Quiros RM; Gattuso P; Ain KB; Prinz RA
Cancer Res; 2003 Aug; 63(15):4561-7. PubMed ID: 12907632
[TBL] [Abstract][Full Text] [Related]
19. Infrequent CDKN2 mutation in human differentiated thyroid cancers.
Tung WS; Shevlin DW; Bartsch D; Norton JA; Wells SA; Goodfellow PJ
Mol Carcinog; 1996 Jan; 15(1):5-10. PubMed ID: 8561866
[TBL] [Abstract][Full Text] [Related]
20. p53 gene mutations in radiation-induced thyroid cancer.
Fogelfeld L; Bauer TK; Schneider AB; Swartz JE; Zitman R
J Clin Endocrinol Metab; 1996 Aug; 81(8):3039-44. PubMed ID: 8768871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
